menu
    • menu
    [{"orgOrder":0,"company":"Citryll","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Inapplicable"},{"orgOrder":0,"company":"Citryll","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Series B Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ Johnson & Johnson"},{"orgOrder":0,"company":"Citryll","sponsor":"ReumaNederland","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Funding","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Citryll \/ ReumaNederland","highestDevelopmentStatusID":"8","companyTruncated":"Citryll \/ ReumaNederland"},{"orgOrder":0,"company":"Citryll","sponsor":"Bom Brabant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"CIT-013","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Citryll","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Citryll \/ Bom Brabant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Citryll \/ Bom Brabant Ventures"}]

    Find Clinical Drug Pipeline Developments & Deals by Citryll

    Menu

    Citryll

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $89.2 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Citryll Raises EUR 85M to Advance NET-Targeting Therapy for Immune Disorders

                            Details : The financing will support the company-lead product CIT-013 monoclonal antibody. It is being evaluated for the treatment of rheumatoid arthritis.

                            Product Name : CIT-013

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            December 09, 2024

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Johnson & Johnson

                            Deal Size : $89.2 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Citryll Completes Dosing in Phase 1 Trial for Anti-Inflammatory Candidate CIT-013

                            Details : CIT-013 offers a novel therapeutic approach for treating inflammatory diseases by targeting NETs, which is being investigated for rheumatoid arthiritis.

                            Product Name : CIT-013

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            July 31, 2024

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : ReumaNederland

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Citryll Collaborates on NET Research for Novel Rheumatoid Arthritis Treatments

                            Details : The proceeds will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013, a first-in-class monoclonal antibody.

                            Product Name : CIT-013

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 10, 2024

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : ReumaNederland

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed

                            Citryll

                            Netherlands arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Bom Brabant Ventures

                            Deal Size : $21.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Citryll Completes € 18.5 M Fundraise to Develop CIT-013, an Antibody Targeting Neutrophil Extracellular Trap...

                            Details : The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).

                            Product Name : CIT-013

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 07, 2020

                            Lead Product(s) : CIT-013

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Bom Brabant Ventures

                            Deal Size : $21.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth